$ABBV AbbVie Submits Regulatory Application to FDA for Risankizumab-rzaa (SKYRIZI®) for the Treatment of Patients 16 Years and Older with Moderate to Severe Crohn’s Disease

on September 20, 2021 News and Tags: , , , with 0 comments
Time:
9:10 AM
Symbol:
ABBV
Source:
PR Newswire
Read more

$ABBV AbbVie and REGENXBIO Announce Eye Care Collaboration

on September 13, 2021 News and Tags: , , , , , , , with 0 comments
Time:
6:30 AM
Symbol:
ABBV
Source:
PR Newswire
Read more

$ABBV AbbVie Declares Quarterly Dividend

on September 10, 2021 News and Tags: , , , with 0 comments
Time:
10:27 AM
Symbol:
ABBV
Source:
PR Newswire
Read more

$ABBV AbbVie to Present Data From Its Migraine Portfolio at the 2021 International Headache Congress

on September 8, 2021 News and Tags: , , , with 0 comments
Time:
9:10 AM
Symbol:
ABBV
Source:
PR Newswire
Read more

$ABBV New England Journal of Medicine Publishes 12-Week Results from Study Evaluating Atogepant for the Preventive Treatment of Migraine

on August 18, 2021 News and Tags: , , , with 0 comments
Time:
5:28 PM
Symbol:
ABBV
Source:
PR Newswire
Read more

$ABBV Mission and AbbVie Collaboration in Alzheimer’s and Parkinson’s Diseases Reaches Next Milestone

on August 9, 2021 News and Tags: , , , with 0 comments
Time:
4:00 AM
Symbol:
ABBV
Source:
Business Wire News Releases
Read more

$ABBV Results from IMBRUVICA® (ibrutinib) RESONATE-2 Study Provide Up to Seven Years of Progression-Free and Overall Survival Data in First-Line Chronic Lymphocytic Leukemia (CLL)

on June 4, 2021 News and Tags: , , , with 0 comments
Time:
9:00 AM
Symbol:
ABBV
Source:
PR Newswire
Read more

$ABBV AbbVie to Present Analysis Evaluating Continuous RINVOQ® (upadacitinib) Treatment in Psoriatic Arthritis for More Than One Year at EULAR 2021 Virtual Congress

on June 2, 2021 News and Tags: , , , with 0 comments
Time:
7:30 AM
Symbol:
ABBV
Source:
PR Newswire
Read more

$ABBV AbbVie to Present at Bernstein’s 37th Annual Strategic Decisions Conference

on May 26, 2021 News and Tags: , , , with 0 comments
Time:
8:15 AM
Symbol:
ABBV
Source:
PR Newswire
Read more

$ABBV AbbVie Presents New Late-Breaking Data Analyses Showing Risankizumab (SKYRIZI®) Achieves Clinical Remission and Endoscopic Response at Week 12 in Patients with Moderate to Severe Crohn’s Disease

on May 24, 2021 News and Tags: , , , with 0 comments
Time:
9:15 AM
Symbol:
ABBV
Source:
PR Newswire
Read more

$ABBV Allergan Aesthetics to Acquire Soliton, Expanding Body Contouring Portfolio

on May 10, 2021 News and Tags: , , , , , , , with 0 comments
Time:
8:30 AM
Symbol:
ABBV
Source:
PR Newswire
Read more